Placebo NDPI

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01822899

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-04-04End: 2013-10-07Updated: 2017-09-06

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01879410

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-06-13End: 2014-01-09Updated: 2017-11-08

Related Papers

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

UNC Libraries2021-06-24

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

2019-06-291 citations

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

BMC Pulmonary Medicine2015-08-1862 citations

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

Respiratory Medicine2015-05-0881 citations